Investment in Natural Rf Life Sciences Inc. managed by CEO Dr. Jacqueline Shan
TSX Venture: QPT
EDMONTON, May 4, 2017 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products to improve the quality of life, today announced that it is making a $500,000 cash investment to acquire 32% of the outstanding common stock of Natural Rf Life Sciences Inc., a private company developing and marketing science based, clinically tested, natural heath products. Natural Rf Life Sciences Inc. was founded and is managed by Dr. Jacqueline Shan, co-creator of Canada's number one colds and flu brand, COLD-FX™. Dr. Shan is prominent throughout the natural health products industry as the scientist leading the development of higher standards for evidence based natural health products, and bringing such products to market using the scientific standards and techniques long established within the pharmaceutical industry.
The first launched product, Allergy-Rf™, is the only natural health product clinically proven in a human study to provide effective, fast acting, multifunctional respiratory relief from seasonal and environmental allergies. Most OTC anti-allergy products block the activity of histamines after they have been released from mast cells during an allergic attack. Allergy-Rf™ may proactively work to prevent the allergens from attacking the body and subsequent releasing of histamines, thereby greatly reducing an allergic response. The efficacy and safety of Allergy-Rf™ has been confirmed in a double-blind, placebo-controlled trial.
"We are excited to work with Quest on this clinically tested natural health product," said Dr. Jacqueline Shan. "Allergy-Rf™ is a 100% naturally sourced alternative to OTC drug products, and is an excellent option for people who suffer from seasonal and environmental allergies."
"We are pleased to expand our consumer health product pipeline beyond Bellus Skin™ Rejuvenation Serum (www.bellusskin.com) and provide consumers with more choices based on scientifically developed, clinically proven natural health products," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "OTC natural health products represent a multibillion dollar market, but most products are unproven in terms of quality or efficacy. We believe our products can distinguish themselves from others and enable us to gain the trust of our customers."
About Natural Rf Life Sciences Inc.
Natural Rf Life Sciences Inc. is a private Canadian company that is focused on developing evidence - based natural therapeutics and building consumer health brands. Natural Rf is currently launching a Health Canada approved (NPN # 80053988), clinically proven natural health product, Allergy-Rf™, previously known as Allergy-FX™, in health food and pharmacy stores across Canada. The company has a pipeline of natural health products and plans to launch more health condition-specific Rf brands in women's health, joint health, stress, pain and cardiovascular health. Natural Rf Life Sciences is also developing its international markets through strategic partnership and distribution agreements with international consumer health and bioscience companies. For more information, please visit www.AllergyRf.com
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded, Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to BioCeltran Co., Ltd., a Korea based company (Bioceltran). Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest also markets consumer health products worldwide, including Bellus Skin™ serum, a premium anti-wrinkle skin care product licensed from Korea. Quest is also developing an antibody licensed from University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Quest PharmaTech Inc.
For further information: Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: firstname.lastname@example.org; Internet: www.questpharmatech.com, www.madencobio.com, www.bellusskin.com